DrugPatentWatch Database Preview
Drugs in Development Information for Ganetespib
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug Ganetespib?
Ganetespib is an investigational drug.
There have been 31 clinical trials for Ganetespib.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., National Cancer Institute (NCI), and Dana-Farber Cancer Institute.
There are twenty-two US patents protecting this investigational drug and three hundred and sixty-nine international patents.
Summary for Ganetespib
| US Patents | 22 |
| International Patents | 369 |
| US Patent Applications | 78 |
| WIPO Patent Applications | 50 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-10-01) |
| Vendors | 57 |
Recent Clinical Trials for Ganetespib
| Title | Sponsor | Phase |
|---|---|---|
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | European Commission | Phase 2 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | Universitaire Ziekenhuizen Leuven | Phase 2 |
| A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer | University of Chicago | N/A |
Clinical Trial Summary for Ganetespib
Top disease conditions for Ganetespib
Top clinical trial sponsors for Ganetespib
US Patents for Ganetespib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ganetespib | Start Trial | Resorcinol derivative as HSP90 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (Lianyungang, CN) | Start Trial |
| Ganetespib | Start Trial | Pyrimidine-diamine dual HSP90/TRAP1 inhibitors | Calasia Pharmaceuticals, Inc. (San Diego, CA) | Start Trial |
| Ganetespib | Start Trial | Block copolymer conjugate of physiologically active substance | Nippon Kayaku Kabushiki Kaisha (Tokyo, JP) | Start Trial |
| Ganetespib | Start Trial | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients | Corning Incorporated (Corning, NY) | Start Trial |
| Ganetespib | Start Trial | Triazole compounds that modulate Hsp90 activity | Synta Pharmaceuticals Corp. (Lexington, MA) | Start Trial |
| Ganetespib | Start Trial | Method for treating proliferative disorders with HSP90 inhibitors | Synta Pharmaceuticals Corp. (Lexington, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ganetespib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ganetespib | Australia | 2016208863 | 2035-01-22 | Start Trial |
| Ganetespib | Canada | 2974756 | 2035-01-22 | Start Trial |
| Ganetespib | China | 107108591 | 2035-01-22 | Start Trial |
| Ganetespib | European Patent Office | 3248968 | 2035-01-22 | Start Trial |
| Ganetespib | Japan | 2018504413 | 2035-01-22 | Start Trial |
| Ganetespib | South Korea | 20170113586 | 2035-01-22 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
